Professor Whitelaw has almost 30 years of industry experience in the life sciences and health care sectors, as an attorney, compliance officer, and consultant. His career has focused on food and drug law and corporate governance, as well as designing and running compliance programs within medical devices, pharmaceutical sales, and marketing and pharmaceutical R&D. He is a licensed food and drug attorney, with a doctorate in Health Law. A former Food and Drug Law Institute (FDLI) fellow, he also worked for the FDA’s Office of Chief Counsel and Deloitte. Dr. Whitelaw has served as a compliance officer for several pharmaceutical and medical device companies including as the Chief Compliance Officer (C.R. Bard, Inc. and Misonix, Inc.), head of pharmaceutical commercial compliance (SmithKline Beecham Pharmaceuticals North America), and global compliance officer for R&D (GlaxoSmithKline). In each case, he has designed, built, and implemented a compliance program from a “blank sheet of paper.” Currently, he is the President & CEO of Whitelaw Compliance Group as well as Editor for the Policy & Medicine Compliance Update, a monthly publication for life science compliance professionals.